Company Overview - Founded on May 18, 1993, and listed on the Shenzhen Stock Exchange on June 16, 1997, the company is a university-affiliated pharmaceutical enterprise with a comprehensive pharmaceutical platform covering research, production, and sales [1] - The company primarily engages in the research, production, and sales of chemical drug formulations, as well as pharmaceutical distribution and medical services, and is classified under the pharmaceutical and biological - chemical pharmaceuticals - chemical formulations sector [1] Financial Performance - For Q3 2025, the company's revenue was 1.231 billion yuan, ranking 44th among 110 companies in the industry, while the industry leader, Huadong Medicine, reported revenue of 32.664 billion yuan [2] - The net profit for the same period was 136 million yuan, placing the company 45th in the industry, with the top performer, Heng Rui Medicine, achieving a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 23.09%, down from 34.01% in the previous year, which is below the industry average of 35.26%, indicating lower debt pressure [3] - The gross profit margin for the same period was 27.03%, slightly down from 27.75% year-on-year, and significantly lower than the industry average of 57.17%, suggesting a need for improvement in profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.88% to 49,400, with an average holding of 12,100 circulating A-shares, which increased by 2.97% [5] - Among the top ten circulating shareholders, Guangfa Quantitative Multi-Factor Mixed A (005225) is the sixth largest, holding 2.278 million shares as a new shareholder [5] Leadership - The controlling shareholder is Southwest Synthetic Pharmaceutical Group Co., Ltd., with Xu Xiren as the actual controller, who is also the chairman of the company and has a background in banking [4]